1. Complement system's role in cancer and its therapeutic potential in ovarian cancer
   H. Bareke et al, 2018, Scand J Immunol CrossRef
2. Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer
   Mark D. Pegram et al, 2018, American Society of Clinical Oncology Educational Book CrossRef
3. Immunotherapy: the good, the bad, the ugly, and the really ugly
   Donald R. Branch, 2019, Transfusion CrossRef
4. Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention
   Zvi Fishelson et al, 2019, Front. Immunol. CrossRef
5. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy
   Anne Geller et al, 2019, Front. Immunol. CrossRef
6. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis
   Li-Chung Tsao et al, 2019 CrossRef
7. Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin® with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology
   Liqi Xie et al, 2020, BioDrugs CrossRef
8. Epitope Molecularly Imprinted Polymer Nanoparticles for Chemo-/Photodynamic Synergistic Cancer Therapy Guided by Targeted Fluorescence Imaging
   Hui Peng et al, 2020, ACS Appl. Mater. Interfaces CrossRef
9. Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy
   Els Lebegge et al, 2020, Front. Immunol. CrossRef
10. Plasma CD59 Concentrations are Increased in Preeclampsia with Severe Features and Correlate with Laboratory Measures of End-Organ Injury
    Jesús A. Velásquez et al, 2020, Pregnancy Hypertension CrossRef
11. The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs.
    Josée Golay et al, 2020, Antibodies (Basel) CrossRef
12. GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets
    Nada H. Hussein et al, 2020, Front. Oncol. CrossRef
13. Sialylation of CD55 by ST3GAL1 Facilitates Immune Evasion in Cancer
    Wen-Der Lin et al, 2021, Cancer Immunol Res CrossRef
14. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength
    Sina Bondza et al, 2021, Front. Immunol. CrossRef
15. Complement in Tumourigenesis and the Response to Cancer Therapy
    Rebecca M. O’Brien et al, 2021, Cancers CrossRef
16. Targeting the Complement Pathway in Malignant Glioma Microenvironments
    Hongtao Zhu et al, 2021, Front. Cell Dev. Biol. CrossRef
17. A structure-based approach for the development of a bicyclic peptide acting as a miniaturized anti-CD55 antibody
    Miguel Moreira et al, 2021, International Journal of Biological Macromolecules CrossRef
18. Clinical value of CD97 and CD55 levels in the differential diagnosis of tuberculous and malignant pleural effusions
    Chunyan Wang et al, 2021 CrossRef
19. Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar
    Parag Goyal et al, 2021, Future Medicinal Chemistry CrossRef
20. Tumor-Sensitive Biodegradable Nanoparticles of Molecularly Imprinted Polymer-Stabilized Fluorescent Zeolitic Imidazolate Framework-8 for Targeted Imaging and Drug Delivery
    Ya-Ting Qin et al, 2020, ACS Appl. Mater. Interfaces CrossRef
21. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
    Li-Chung Tsao et al, 2021, Cancer Res CrossRef
22. Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients.
    Sangwoo S Kim et al, 2021, Clin Cancer Res CrossRef
23. Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis
    Li-Chung Tsao et al, 2022 CrossRef
24. Human Primary Airway Basal Cells Display a Continuum of Molecular Phases from Health to Disease in Chronic Obstructive Pulmonary Disease
    Sofia C. Wijk et al, 2021, Am J Respir Cell Mol Biol CrossRef
25. CD55 in cancer: Complementing functions in a non-canonical manner
    Rashmi Bharti et al, 2022, Cancer Letters CrossRef
26. Heterogeneity and Functions of Tumor-Infiltrating Antibody Secreting Cells: Lessons from Breast, Ovarian, and Other Solid Cancers
    Yasmine Lounici et al, 2022, Cancers CrossRef
27. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies
    Sanghwan Ko et al, 2022, Exp Mol Med CrossRef
28. NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59
    Sung Wook Son et al, 2022, Sci Rep CrossRef
29. Extracellular Vesicle Membrane Protein Profiling and Targeted Mass Spectrometry Unveil CD59 and Tetraspanin 9 as Novel Plasma Biomarkers for Detection of Colorectal Cancer
    Srinivas Dash et al, 2022, Cancers CrossRef
30. miR-132-3p regulates antibody-mediated complement-dependent cytotoxicity in colon cancer cells by directly targeting CD55
    Yu Fan et al, 2022 CrossRef
31. null
    Sofia Álvarez-Lorenzo et al, 2023 CrossRef
32. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
    Nina E. Weisser et al, 2023, Nat Commun CrossRef
33. Improvement of Antibody Activity by Controlling Its Dynamics Using the Glycan–Lectin Interaction
    Yoshiyuki Manabe et al, 2023, Angew Chem Int Ed CrossRef
34. Improvement of Antibody Activity by Controlling Its Dynamics Using the Glycan–Lectin Interaction
    Yoshiyuki Manabe et al, 2023, Angewandte Chemie CrossRef
35. Bispecific Complement Engagers for Targeted Complement Activation
    Dennis V. Pedersen et al, 2023 CrossRef
36. Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20
    Sang Min Lee et al, 2023, Sci Rep CrossRef
37. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
    Xiaohan Guo et al, 2023, Front. Immunol. CrossRef